Our member AstraZeneca has announced their first half performance reports. Big congratulations to them for their positive product development and financial surplus!
On 29 July 2022, AstraZeneca launched a press release. Pascal Soriot, Chief Executive Officer, commenting on the results said that they have been successful in terms of saving more than six million lives for their Covid-19 Vaxzevria, and have made great research contributions in sharing valuable practice-changing data for medicines, including Enhertu in breast cancer, Farxiga in heart failure and Ultomiris in neuromyelitis optica spectrum disorder.
The SweCham would like to give a big shout out to AstraZeneca for their efforts in investing their financial success in a greater R&D to save more lives and to ensure sustainable growth!
To read more, please visit https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2022/h1-2022-results.html